Oncologie

, Volume 11, Issue 11, pp 507–532

Prise en charge du cancer du sein infiltrant de la femme non ménopausée

Recommandations / Recommendations

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Références

  1. 1.
    ACR BI-RADS — Mammographie. Deuxième édition franc basée sur la quatrième édition américaine, 2004. American College of Radiology (ACR). ACR-BI-RADS — Mammography. In: ACR Breast-imaging reporting and data system, Breast Imaging Atlas. Reston, VA: American College of Radiology, 2003Google Scholar
  2. 2.
    ACR (2008) Practice guideline for the performance of magnetic resonance imaging (MRI) of the breast. American College of Radiology. Consulté sur: www.acr.org.Google Scholar
  3. 3.
    Ahn SH, Son BH, Kim SW, et al. (2007) Poor outcome of hormone receptor-positive breast cancer at very young age is due to tamoxifen resistance: nationwide survival data in Korea: a report from the Korean Breast Cancer Society. J Clin Oncol 25: 2360–2368PubMedCrossRefGoogle Scholar
  4. 4.
    Albain KS, Allred DC, Clark GM (1994) Breast cancer outcome and predictors of outcome: are there age differentials? J Natl Cancer Inst Monogr: 35–42Google Scholar
  5. 5.
    Alvarez S, Añorbe E, Alcorta P, et al. (2006) Role of sonography in the diagnosis of axillary lymph node metastases in breast cancer: a systematic review. Am J Roentgenol 186: 1342–1348CrossRefGoogle Scholar
  6. 6.
    Anastassiades O, Iakovou E, Stavridou N, et al. (1993) Multicentricity in breast cancer. A study of 366 cases. Am J Clin Pathol 99: 238–243PubMedGoogle Scholar
  7. 7.
    Anderson PR, Freedman G, Nicolaou N, et al. (2009) Postmastectomy chest wall radiation to a temporary tissue expander or permanent breast implant: is there a difference in complication rates? Int J Radiat Oncol Biol Phys 74(1): 81–85PubMedGoogle Scholar
  8. 8.
    Antoniou A, Pharoah PD, Narod S, et al. (2003) Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 72: 1117–1130PubMedCrossRefGoogle Scholar
  9. 9.
    Aref I, Cross P (2000) Conservative surgery and radiation therapy for early-stage breast cancer after previous mantle radiation for Hodgkin’s disease. Br J Radiol73: 905–906PubMedGoogle Scholar
  10. 10.
    Arnaout-Alkarain A, Kahn HJ, Narod SA, et al. (2007) Significance of lymph vessel invasion identified by the endothelial lymphatic marker D2-40 in node-negative breast cancer. Mod Pathol 20: 183–191PubMedCrossRefGoogle Scholar
  11. 11.
    Arriagada R, Le MG, Rochard F, Contesso G (1996) Conservative treatment versus mastectomy in early breast cancer: patterns of failure with 15 years of follow-up data. Institute Gustave-Roussy Breast Cancer Group. J Clin Oncol 14: 1558–1564PubMedGoogle Scholar
  12. 12.
    Arriagada R, Lê MG, Spielmann M, et al. (2005) Randomized trial of adjuvant ovarian suppression in 926 premenopausal patients with early breast cancer treated with adjuvant chemotherapy. Ann Oncol 16(3): 389–396PubMedCrossRefGoogle Scholar
  13. 13.
    Arriagada R, Mouriesse H, Sarrazin D, et al. (1985) Radiotherapy alone in breast cancer. I. Analysis of tumor parameters, tumor dose and local control: the experience of the Gustave-Roussy Institute and the Princess Margaret Hospital. Int J Radiat Oncol Biol Phys 11: 1751–1757PubMedGoogle Scholar
  14. 14.
    Bartelink H, Boersma LJ, Leer JW, Poortmans P (2004) The Intergroup Trial of the BOOG “The Young Boost Trial” BOOG 2004-01; CKTO 2003-13. Radiation dose intensity study in breast cancer in young women: a randomized phase III trial of additional dose to the tumor bedGoogle Scholar
  15. 15.
    Bartelink H, Horiot JC, Poortmans P, et al. (2001) Recurrence rates after treatment of breast cancer with standard radiotherapy with or without additional radiation. N Engl J Med 345: 1378–1387PubMedCrossRefGoogle Scholar
  16. 16.
    Bartelink H, Horiot JC, Poortmans PM, et al. (2007) Impact of a higher radiation dose on local control and survival in breastconserving therapy of early breast cancer: 10-year results of the randomized boost versus no boost EORTC 22881-10882 trial. J Clin Oncol 25: 3259–3265PubMedCrossRefGoogle Scholar
  17. 17.
    Beadle BM, Woodward WA, Tucker SL, et al. (2008) Tenyear recurrence rates in young women with breast cancer by locoregional treatment approach. Int J Radiat Oncol Biol PhysGoogle Scholar
  18. 18.
    Benda RK, Yasuda G, Sethi A, et al. (2003) Breast boost: are we missing the target? Cancer 97: 905–909PubMedCrossRefGoogle Scholar
  19. 19.
    Bentzon N, During M, Rasmussen BB, Mouridsen H, et al. (2008) Prognostic effect of estrogen receptor status across age in primary breast cancer. Int J Cancer 122: 1089–1094PubMedCrossRefGoogle Scholar
  20. 20.
    Berg WA, Gutierrez L, NessAiver MS, et al. (2004) Diagnostic accuracy of mammography, clinical examination, US, and MR imaging in preoperative assessment of breast cancer. Radiology 233: 830–849PubMedCrossRefGoogle Scholar
  21. 21.
    Bines J, Oleske DM, Cobleigh MA (1996) Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol 14: 1718–1729PubMedGoogle Scholar
  22. 22.
    Black D, Specht M, Lee JM, et al. (2007) Detecting occult malignancy in prophylactic mastectomy: preoperative MRI versus sentinel lymph node biopsy. Ann Surg Oncol 14(9): 2477–2484PubMedCrossRefGoogle Scholar
  23. 23.
    Blichert-Toft M, Rose C, Andersen JA, et al. (1992) Danish randomized trial comparing breast conservation therapy with mastectomy: six years of life-table analysis. Danish Breast Cancer Cooperative Group. J Natl Cancer Inst Monogr (11): 19–25Google Scholar
  24. 24.
    Boetes C, Mus RD, Holland R, et al. (1995) Breast tumors: comparative accuracy of MR imaging relative to mammography and US for demonstrating extent. Radiology 197: 743–747PubMedGoogle Scholar
  25. 25.
    Bollet MA, Sigal-Zafrani B, Mazeau V, et al. (2007) Age remains the first prognostic factor for locoregional breast cancer recurrence in young (< 40 years) women treated with breastconserving surgery first. Radiother Oncol 82: 272–280PubMedCrossRefGoogle Scholar
  26. 26.
    Boughey JC, Cormier JN, Xing Y, et al. (2007) Decision analysis to assess the efficacy of routine sentinel lymphadenectomy in patients undergoing prophylactic mastectomy. Cancer 110(11): 2542–2550PubMedCrossRefGoogle Scholar
  27. 27.
    Buchholz TA, Tucker SL, Erwin J, et al. (2001) Impact of systemic treatment on local control for patients with lymph node-negative breast cancer treated with breast-conservation therapy. J Clin Oncol 19: 2240–2246PubMedGoogle Scholar
  28. 28.
    Carey LA, Perou CM, Livasy CA, et al. (2006) Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 295: 2492–2502PubMedCrossRefGoogle Scholar
  29. 29.
    Casalini P, Carcangiu ML, Tammi R, et al. (2008) Two distinct local relapse subtypes in invasive breast cancer: effect on their prognostic impact. Clin Cancer Res 14: 25–31PubMedCrossRefGoogle Scholar
  30. 30.
    Chen AM, Meric-Bernstam F, Hunt KK, et al. (2004) Breast conservation after neoadjuvant chemotherapy: the MD Anderson cancer center experience. J Clin Oncol 22: 2303–2312PubMedCrossRefGoogle Scholar
  31. 31.
    Chia S, Bryce C, Gelmon K (2005) The 2000 EBCTCG overview: a widening gap. Lancet 365(9472): 1665–1666PubMedCrossRefGoogle Scholar
  32. 32.
    Clark RM, Whelan T, Levine M, et al. (1996) Randomized clinical trial of breast irradiation following lumpectomy and axillary dissection for node-negative breast cancer: an update. Ontario Clinical Oncology Group. J Natl Cancer Inst 88: 1659–1664PubMedCrossRefGoogle Scholar
  33. 33.
    Clarke M, Collins R, Darby S, et al. (2005) Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 366: 2087–2106PubMedGoogle Scholar
  34. 34.
    Clemons M (2007) Identifying menopause in breast cancer patients: considerations and implications. Breast Cancer Res Treat 104: 115–120PubMedCrossRefGoogle Scholar
  35. 35.
    Colleoni M, Gelber S, Goldhirsch A, et al. (2006) Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group Trial 13–93. J Clin Oncol 24: 1332–1341PubMedCrossRefGoogle Scholar
  36. 36.
    Colleoni M, Rotmensz N, Peruzzotti G, et al. (2006) Role of endocrine responsiveness and adjuvant therapy in very young women (below 35 years) with operable breast cancer and nodenegative disease. Ann Oncol 17: 1497–1503PubMedCrossRefGoogle Scholar
  37. 37.
    Coulombe G, Tyldesley S, Speers C, et al. (2007) Is mastectomy superior to breast-conserving treatment for young women? Int J Radiat Oncol Biol Phys 67(5): 1282–1290PubMedGoogle Scholar
  38. 38.
    Cowen D, Houvenaeghel G, Bardou V, et al. (2000) Local and distant failures after limited surgery with positive margins and radiotherapy for node-negative breast cancer. Int J Radiat Oncol Biol Phys 47: 305–312PubMedCrossRefGoogle Scholar
  39. 39.
    Cuzick J, Ambroisine L, Davidson N, et al. (2007) Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptorpositive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials. Lancet 369(9574): 1711–1723PubMedCrossRefGoogle Scholar
  40. 40.
    Davidson NE, O’Neill AM, Vukov AM, et al. (2005) Chemoendocrine therapy for premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer: results from INT 0101 (E5188). J Clin Oncol 23(25): 5973–5982PubMedCrossRefGoogle Scholar
  41. 41.
    de Bock GH, van der Hage JA, Putter H, et al. (2006) Isolated locoregional recurrence of breast cancer is more common in young patients and following breast conserving therapy: longterm results of European Organisation for Research and Treatment of Cancer studies. Eur J Cancer 42(3): 351–356PubMedCrossRefGoogle Scholar
  42. 42.
    Del Mastro L, Catzeddu T, Boni L, et al. (2006) Prevention of chemotherapy-induced menopause by temporary ovarian suppression with goserelin in young, early breast cancer patients. Ann Oncol 17(1): 74–78PubMedCrossRefGoogle Scholar
  43. 43.
    Deutsch M, Gerszten K, Bloomer WD, Avisar E (2001) Lumpectomy and breast irradiation for breast cancer arising after previous radiotherapy for Hodgkin’s disease or lymphoma. Am J Clin Oncol 24: 33–34PubMedCrossRefGoogle Scholar
  44. 44.
    Drew PJ, Harvey I, Hanby A, et al. (2008) The UK NIHR multicentre randomised COMICE trial of MRI planning for breast conserving treatment for breast cancer. SABCS, (abstract 51)Google Scholar
  45. 45.
    Durieux A (2006) Prognosis of operable breast cancer in young patients treated in a single institution: independent pejorative value of positive estrogen receptor. Eur J Cancer 4: S130Google Scholar
  46. 46.
    Easton DF, Hopper JL, Thomas DC, et al. (2004) Breast cancer risks for BRCA1/2 carriers. Science 306(5705): 2187–2191PubMedCrossRefGoogle Scholar
  47. 47.
    Eccles D, Gerty S, Simmonds P, et al. (2007) POSH Steering Group. Prospective study of outcomes in sporadic versus hereditary breast cancer (POSH): study protocol. BMC Cancer 7: 160PubMedCrossRefGoogle Scholar
  48. 48.
    Eisinger F, Bressac B, Castaigne D, et al. (2004) Identification and management of hereditary breast/ovarian cancers (2004 update). Bull Cancer 91: 219–237PubMedGoogle Scholar
  49. 49.
    Elkhuizen PH, van Slooten HJ, Clahsen PC, et al. (2000) High local recurrence risk after breast-conserving therapy in nodenegative premenopausal breast cancer patients is greatly reduced by one course of perioperative chemotherapy: a European Organization for Research and Treatment of Cancer Breast Cancer Cooperative Group Study. J Clin Oncol 18: 1075–1083PubMedGoogle Scholar
  50. 50.
    Fischer U, Zachariae O, Baum F, et al. (2004) The influence of preoperative MRI of the breasts on recurrence rate in patients with breast cancer. Eur Radiol 14: 1725–1731PubMedGoogle Scholar
  51. 51.
    Fisher B, Anderson S, Bryant J, et al. (2002) Twenty-year followup of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med 347: 1233–1241PubMedCrossRefGoogle Scholar
  52. 52.
    Fisher B, Anderson S, Fisher ER, et al. (1991) Significance of ipsilateral breast tumor recurrence after lumpectomy. Lancet 338: 327–331PubMedCrossRefGoogle Scholar
  53. 53.
    Forman DL, Chiu J, Restifo RJ, et al. (1998) Breast reconstruction in previously irradiated patients using tissue expanders and implants: a potentially unfavorable result. Ann Plast Surg 40: 360–363; discussion 363–4PubMedCrossRefGoogle Scholar
  54. 54.
    Fornier MN, Modi S, Panageas KS, et al. (2005) Incidence of chemotherapy-induced, long-term amenorrhea in patients with breast carcinoma age 40 years and younger after adjuvant anthracycline and taxane. Cancer 104(8): 1575–1579PubMedCrossRefGoogle Scholar
  55. 55.
    Fortin A, Larochelle M, Laverdiere J, et al. (1999) Local failure is responsible for the decrease in survival for patients with breast cancer treated with conservative surgery and postoperative radiotherapy. J Clin Oncol 17: 101–109PubMedGoogle Scholar
  56. 56.
    Genta F, Zanon E, Camanni M, et al. (2007) Cost/accuracy ratio analysis in breast cancer patients undergoing ultrasoundguided fine-needle aspiration cytology, sentinel-node biopsy, and frozen section of node. World J Surg 31: 1155–1163PubMedCrossRefGoogle Scholar
  57. 57.
    Giacalone PL, Laffargue F, Benos P (1999) Chemotherapy for breast carcinoma during pregnancy: a French national survey. Cancer 86: 2266–2272PubMedCrossRefGoogle Scholar
  58. 58.
    Goldhirsch A, Wood WC, Gelber RD, et al. (2007) Progress and promise: highlights of the international expert consensus on the primary therapy of early-breast cancer. Ann Oncol 18(7): 1133–1144PubMedCrossRefGoogle Scholar
  59. 59.
    Graves KD, Peshkin BN, Halbert CH, et al. (2007) Predictors and outcomes of contralateral prophylactic mastectomy among breast cancer survivors. Breast Cancer Res Treat 104(3): 321–329PubMedCrossRefGoogle Scholar
  60. 60.
    Grobmyer SR, Mortellaro VE, Marshall J, et al. (2008) Is there a role for routine use of MRI in selection of patients for breast-conserving cancer therapy? J Am Coll Surg 206: 104–150Google Scholar
  61. 61.
    Gulati AP, Domchek SM (2008) The clinical management of BRCA1 and BRCA2 mutation carriers. Curr Oncol Rep 10(1): 47–53PubMedCrossRefGoogle Scholar
  62. 62.
    Gwin JL, Eisenberg BL, Hoffman JP, et al. (1993) Incidence of gross and microscopic carcinoma in specimens from patients with breast cancer after re-excision lumpectomy. Ann Surg 218: 729–734PubMedCrossRefGoogle Scholar
  63. 63.
    Haffty BG, Fischer D, Rose M, et al. (1991) Prognostic factors for local recurrence in the conservatively treated breast cancer patient: a cautious interpretation of the data. J Clin Oncol 9: 997–1003PubMedGoogle Scholar
  64. 64.
    Haffty BG, Harrold E, Khan AJ, et al. (2002) Outcome of conservatively managed early-onset breast cancer by BRCA1/2 status. Lancet 359(9316): 1471–1477PubMedCrossRefGoogle Scholar
  65. 65.
    Haffty BG, Wilmarth L, Wilson L, et al. (1994) Adjuvant systemic chemotherapy and hormonal therapy. Effect on local recurrence in the conservatively treated breast cancer patient. Cancer 73: 2543–2548PubMedCrossRefGoogle Scholar
  66. 66.
    Han HS (2008) Analysis of chemotherapy-induced amenorrhea rates by three different anthracycline and taxane containing regimens for early-breast cancer. Breast Cancer Res TreatGoogle Scholar
  67. 67.
    Hartmann LC, Schaid DJ, Woods JE, et al. (1999) Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med 340(2): 77–84PubMedCrossRefGoogle Scholar
  68. 68.
    Hartsell WF, Recine DC, Griem KL, Murthy AK (1995) Delaying the initiation of intact breast irradiation for patients with lymph node-positive breast cancer increases the risk of local recurrence. Cancer 76: 2497–2503PubMedCrossRefGoogle Scholar
  69. 69.
    Hayes DF (2005) Prognostic and predictive factors for breast cancer: translating technology to oncology. J Clin Oncol 23(8): 1596–1597PubMedCrossRefGoogle Scholar
  70. 70.
    Heemskerk-Gerritsen BA, Brekelmans CT, Menke-Pluymers MB, et al. (2007) Prophylactic mastectomy in BRCA1/2 mutation carriers and women at risk of hereditary breast cancer: longterm experiences at the Rotterdam Family Cancer Clinic. Ann Surg Oncol 14(12): 3335–3344PubMedCrossRefGoogle Scholar
  71. 71.
    Herrinton LJ, Barlow WE, Yu O, et al. (2005) Efficacy of prophylactic mastectomy in women with unilateral breast cancer: a cancer research network project. J Clin Oncol 23(19): 4275–4286PubMedCrossRefGoogle Scholar
  72. 72.
    Higgins MJ, Davidson NE (2009) What is the current status of ovarian suppression-ablation in women with premenopausal early-stage breast cancer? Curr Oncol Rep 11(1): 45–50PubMedCrossRefGoogle Scholar
  73. 73.
    Hixson GL (2008) A limitation of ACRIN DMIST. Radiology 248: 702–703PubMedCrossRefGoogle Scholar
  74. 74.
    Holland R, Veling SHJ, Mravunac M, Hendricks JHCL (1985) Histologic multifocality of Tis, T1–2 breast carcinomas: implications for clinical trials of breast-conserving surgery. Cancer 56: 979–990PubMedCrossRefGoogle Scholar
  75. 75.
    Hollingsworth AB, Stough RG, O’Dell CA, Brekke CE (2008) Breast magnetic resonance imaging for preoperative locoregional staging. Am J Surg 196: 389–397PubMedCrossRefGoogle Scholar
  76. 76.
    Holwitt DM, Swatske ME, Gillanders WE et al. (2008) The combination of axillary ultrasound and ultrasound-guided biopsy is an accurate predictor of axillary stage in clinically nodenegative breast cancer patients. Am J Surg 196: 477–482PubMedCrossRefGoogle Scholar
  77. 77.
    Houssami N, Ciatto S, Macaskill P, et al. (2008) Accuracy and surgical impact of magnetic resonance imaging in breast cancer staging: systematic review and meta-analysis in detection of multifocal and multicentric disease. J Clin Oncol 26: 3248–3258PubMedCrossRefGoogle Scholar
  78. 78.
    Houvenaeghel G, Lambaudie E, Buttarelli M, et al. (2008) Bull Cancer 95(12): 1161–1170PubMedGoogle Scholar
  79. 79.
    IBCSG — International Breast Cancer Study Group, Castiglione-Gertsch M, O’Neill A, et al. (2003) Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: a randomized trial. J Natl Cancer Inst 95(24): 1833–1846PubMedGoogle Scholar
  80. 80.
    Ibrahim EM, Ezzat AA, Baloush A, et al. (2000) Pregnancyassociated breast cancer: a case-control study in a young population with a high-fertility rate. Med Oncol 17: 293–300PubMedCrossRefGoogle Scholar
  81. 81.
    Imamura H, Haga S, Shimizu T, et al. (2000) Relationship between the morphological and biological characteristics of intraductal components accompanying invasive ductal breast carcinoma and patient age. Breast Cancer Res Treat 62: 177–184PubMedCrossRefGoogle Scholar
  82. 82.
    Jacobi CE, de Bock GH, Siegerink B, van Asperen CJ (2009) Differences and similarities in breast cancer risk assessment models in clinical practice: which model to choose? Breast Cancer Res Treat 115(2): 381–390PubMedCrossRefGoogle Scholar
  83. 83.
    Jacobson JA, Danforth DN, Cowan KH, et al. (1995) Ten-year results of a comparison of conservation with mastectomy in the treatment of stage I and II breast cancer. N Engl J Med 332: 907–911PubMedCrossRefGoogle Scholar
  84. 84.
    Jonat W, Kaufmann M, Sauerbrei W, et al. (2002) Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: The Zoladex Early Breast Cancer Research Association Study. J Clin Oncol 20(24): 4628–4635PubMedCrossRefGoogle Scholar
  85. 85.
    Jugenburg M, Disa JJ, Pusic AL, Cordeiro PG (2007) Impact of radiotherapy on breast reconstruction. Clin Plast Surg 34: 29–37; abstract V–VIPubMedCrossRefGoogle Scholar
  86. 86.
    Kaufmann M, Graf E, Jonat W, et al. (2007) A randomised trial of goserelin versus control after adjuvant, risk-adapted chemotherapy in premenopausal patients with primary breast cancer — GABG-IV B-93. Eur J Cancer 43(16): 2351–2358PubMedCrossRefGoogle Scholar
  87. 87.
    Kemperman H, Borger J, Hart A, et al. (1995) Prognostic factors for survival after breast-conserving therapy for stage I and II breast cancer. The role of local recurrence. Eur J Cancer 31A: 690–698PubMedCrossRefGoogle Scholar
  88. 88.
    Kirova YM, Stoppa-Lyonnet D, Savignoni A, et al. (2005) Risk of breast cancer recurrence and contralateral breast cancer in relation to BRCA1 and BRCA2 mutation status following breastconserving surgery and radiotherapy. Eur J Cancer 41(15): 2304–2311PubMedCrossRefGoogle Scholar
  89. 89.
    Klijn JGM, Geel van B, Meijers-Heijboer H, et al. (2004) Results of the extended series on prophylactic mastectomy versus surveillance in BRCA1/2 mutation carriers in Rotterdam. Breast Cancer Res Treat (supplement 1), abstract P10–S10 88Google Scholar
  90. 90.
    Kopans DB (2008) DMIST Results: Technologic or observer variability? Radiology 248: 703–704PubMedCrossRefGoogle Scholar
  91. 91.
    Krueger EA, Wilkins EG, Strawderman M, et al. (2001) Complications and patient satisfaction following expander/implant breast reconstruction with and without radiotherapy. Int J Radiat Oncol Biol Phys 49: 713–721PubMedGoogle Scholar
  92. 92.
    Kuhl CK, Schrading S, Leutner CC, et al. (2005) Mammography, breast ultrasound, and magnetic resonance imaging for surveillance of women at high familial risk for breast cancer. J Clin Oncol 23(33): 8469–8476PubMedCrossRefGoogle Scholar
  93. 93.
    Kurtz JM, Jacquemier J, Amalric R, et al. (1990a) Why are local recurrences after breast-conserving therapy more frequent in younger patients? J Clin Oncol 8: 591–598PubMedGoogle Scholar
  94. 94.
    Kurtz JM, Jacquemier J, Amalric R, et al. (1990b) Risk factors for breast recurrence in premenopausal and postmenopausal patients with ductal cancers treated by conservation therapy. Cancer 65: 1867–1878PubMedCrossRefGoogle Scholar
  95. 95.
    Kurtz JM (1992) Factors influencing the risk of local recurrence in the breast. Eur J Cancer 28: 660–666PubMedCrossRefGoogle Scholar
  96. 96.
    Landis DM, Luo W, Song J, et al. (2007) Variability among breast radiation oncologists in delineation of the postsurgical lumpectomy cavity. Int J Radiat Oncol Biol Phys 67: 1299–1308PubMedGoogle Scholar
  97. 97.
    Leach MO, Boggis CR, Dixon AK, et al. (2005) Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer a prospective multicentre cohort study (MARIBS). Lancet 365: 1769–1778PubMedCrossRefGoogle Scholar
  98. 98.
    Lehman CD, Gatsonis C, Kuhl CK et al. (2007) MRI evaluation of the contralateral breast in women with recently diagnosed breast cancer. N Engl J Med 356: 1295–1303PubMedCrossRefGoogle Scholar
  99. 99.
    Lenhard MS, Bauerfeind I, Untch M (2008) Breast cancer and pregnancy: challenges of chemotherapy. Crit Rev Oncol Hematol 67: 196–203PubMedCrossRefGoogle Scholar
  100. 100.
    Levine MN, Bramwell V, Abu-Zahra H, et al. (1992) The effect of systemic adjuvant chemotherapy on local breast recurrence in node-positive breast cancer patients treated by lumpectomy without radiation. Br J Cancer 65: 130–132PubMedGoogle Scholar
  101. 101.
    Lidereau R, Eisinger F, Champeme MH, et al. (2000) Major improvement in the efficacy of BRCA1 mutation screening using morphoclinical features of breast cancer. Cancer Res 60: 1206–1210PubMedGoogle Scholar
  102. 102.
    Liebens FP, Carly B, Pastijn A, Rozenberg S (2007) Management of BRCA1/2 associated breast cancer: a systematic qualitative review of the state of knowledge in 2006. Eur J Cancer 43(2): 238–257PubMedCrossRefGoogle Scholar
  103. 103.
    Liljegren G, Holmberg L, Bergh J, et al. (1999) 10-year results after sector resection with or withhout postoperative radiotherapy for stage I breast cancer: a randomized trial. J Clin Oncol 17: 2326–2333PubMedGoogle Scholar
  104. 104.
    Livi L, Paiar F, Simontacchi G, et al. (2006) Locoregional failure pattern after lumpectomy and breast irradiation in 4,185 patients with T1 and T2 breast cancer. Implications for nodal irradiation. Acta Oncol 45: 564–570PubMedCrossRefGoogle Scholar
  105. 105.
    Lostumbo L, Carbine N, Wallace J, Ezzo J (2004) Prophylactic mastectomy for the prevention of breast cancer. Cochrane Database Syst Rev (4): CD002748PubMedGoogle Scholar
  106. 106.
    Mann RM, Kuhl CK, Kinkel K, Boetes C (2008) Breast MRI: guidelines from the European Society of Breast Imaging. Eur Radiol 18: 1307–1318PubMedCrossRefGoogle Scholar
  107. 107.
    Mathelin C (2008) Insuffisance ovarienne après chimiothérapie pour cancer mammaire. Bull Cancer 95(4): 403–412PubMedGoogle Scholar
  108. 108.
    Mauri D, Pavlidis N, Ioannidis JP (2005) Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. J Natl Cancer Inst 97: 188–194PubMedCrossRefGoogle Scholar
  109. 109.
    McDaniel SM, Rumer KK, Biroc SL, et al. (2006) Remodeling of the mammary microenvironment after lactation promotes breast tumor cell metastasis. Am J Pathol 168: 608–620PubMedCrossRefGoogle Scholar
  110. 110.
    McIntosh A, Freedman G, Eisenberg D, Anderson P (2007) Recurrence rates and analysis of close or positive margins in patients treated without re-excision before radiation for breast cancer. Am J Clin Oncol 30: 146–151PubMedCrossRefGoogle Scholar
  111. 111.
    Meijers-Heijboer H, Brekelmans CT, Menke-Pluymers M, et al. (2003) Use of genetic testing and prophylactic mastectomy and oophorectomy inwomenwith breast or ovarian cancer fromfamilieswith a BRCA1 or BRCA2 mutation. J Clin Oncol 21(9): 1675–1681PubMedCrossRefGoogle Scholar
  112. 112.
    Meijers-Heijboer H, van Geel B, van Putten WL, et al. (2001) Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 345(3): 159–164PubMedCrossRefGoogle Scholar
  113. 113.
    Ménard S, Balsari A, Tagliabue E, et al. (2008) Biology, prognosis and response to therapy of breast carcinomas according to HER2 score. Ann Oncol 19: 1706–1712PubMedCrossRefGoogle Scholar
  114. 114.
    Metcalfe KA, Lubinski J, Ghadirian P, et al. (2008) Predictors of contralateral prophylactic mastectomy in women with a BRCA1 or BRCA2 mutation: the Hereditary Breast Cancer Clinical Study Group. J Clin Oncol 26(7): 1093–1097PubMedCrossRefGoogle Scholar
  115. 115.
    Michel RM, Aguilar JL, Arrieta O (2007) Human chorionic gonadotropin as an angiogenic factor in breast cancer during pregnancy. Med Hypotheses 68: 1035–1040PubMedCrossRefGoogle Scholar
  116. 116.
    Mir O, Berveiller P, Ropert S, et al. (2008) Emerging therapeutic options for breast cancer chemotherapy during pregnancy. Ann Oncol 19: 607–613PubMedCrossRefGoogle Scholar
  117. 117.
    Montgomery LL, Tran KN, Heelan MC, et al. (1999) Issues of regret in women with contralateral prophylactic mastectomies. Ann Surg Oncol 6(6): 546–552PubMedCrossRefGoogle Scholar
  118. 118.
    Moon WK, Noh DY, Im JG (2002) Multifocal, multicentric, and contralateral breast cancers: bilateral whole-breast US in the preoperative evaluation of patients. Radiology 224: 569–576PubMedCrossRefGoogle Scholar
  119. 119.
    Navrozoglou I, Vrekoussis T, Kontostolis E, et al. (2008) Breast cancer during pregnancy: a mini-review. Eur J Surg Oncol 34: 837–843PubMedGoogle Scholar
  120. 120.
    NCCN (2008) Update V.I. (www://http. Nccn.org)Google Scholar
  121. 121.
    NCCN, National Comprehensive Cancer Network (2007) Principles of dedicated breast MRI testing. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer version. Available from: URL: www.ncnn.orgGoogle Scholar
  122. 122.
    NICE clinical guideline 41 update October 2006 (www://http.nice.org.uk/guidance)Google Scholar
  123. 123.
    Nogués C (2008) Communication orale. Sociétéfrancaise de sénologie et de pathologie mammaire. LabauleGoogle Scholar
  124. 124.
    Noruzinia M, Coupier I, Pujol P (2005) Is BRCA1/BRCA2-related breast carcinogenesis estrogen-dependent? Cancer 104(8): 1567–1574PubMedCrossRefGoogle Scholar
  125. 125.
    Nuyten DS, Kreike B, Hart AA, et al. (2006) Predicting a local recurrence after breast-conserving therapy by gene expression profiling. Breast Cancer Res 8: R62PubMedCrossRefGoogle Scholar
  126. 126.
    Oh JL, Bonnen M, Outlaw ED et al. (2006) The impact of young age on locoregional recurrence after doxorubicin-based breast conservation therapy in patients 40 years old or younger: How young is “.young.”? Int J Radiat Oncol Biol Phys 65: 1345–1352PubMedGoogle Scholar
  127. 127.
    Oh JL, Nguyen G, Whitman, GJ, et al. (2007) Placement of radiopaque clips for tumor localization in patients undergoing neoadjuvant chemotherapy and breast conservation therapy. Cancer 110: 2420–2427PubMedCrossRefGoogle Scholar
  128. 128.
    Ortmann O, Cufer T, Dixon JM, et al. (2009) Adjuvant endocrine therapy for perimenopausal women with early breast cancer. Breast 18(1): 2–7PubMedCrossRefGoogle Scholar
  129. 129.
    Pant S, Landon MB, Blumenfeld M, et al. (2008) Treatment of breast cancer with trastuzumab during pregnancy. J Clin Oncol 26: 1567–1569PubMedCrossRefGoogle Scholar
  130. 130.
    Park CC, Mitsumori M, Nixon A, et al. (2000) Outcome at 8 years after breast-conserving surgery and radiation therapy for invasive breast cancer: influence of margin status and systemic therapy on local recurrence. J Clin Oncol 18: 1668–1675PubMedGoogle Scholar
  131. 131.
    Parton M, Smith IE (2008) Controversies in the management of patients with breast cancer: adjuvant endocrine therapy in premenopausal women. J Clin Oncol 26(5): 745–752PubMedCrossRefGoogle Scholar
  132. 132.
    Partridge AH (2005) Young women’s preferences about adjuvant endocrine therapy for breast cancer. Lancet Oncol 6(8): 542–544PubMedCrossRefGoogle Scholar
  133. 133.
    Peralta EA, Ellenhorn JD, Wagman LD, et al. (2000) Contralateral prophylactic mastectomy improves the outcome of selected patients undergoing mastectomy for breast cancer. Am J Surg 180(6): 439–445PubMedCrossRefGoogle Scholar
  134. 134.
    Perez CA (2003) Conservation therapy in T1-T2 breast cancer: past, current issues, and future challenges and opportunities. Cancer J 9: 442–453PubMedCrossRefGoogle Scholar
  135. 135.
    Pestalozzi BC, Zahrieh D, Mallon E, et al. Distinct clinical and prognostic features of infiltrating lobular carcinoma of the breast: combined results of 15th International Breast Cancer Study Group clinical trials. J Clin Oncol 26: 3006–3014Google Scholar
  136. 136.
    Pierce LJ, Levin AM, Rebbeck TR, et al. (2006) Ten-year multiinstitutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stages I/II breast cancer. J Clin Oncol 24(16): 2437–2443PubMedCrossRefGoogle Scholar
  137. 137.
    Pisano ED, Gatsonis CA, Yaffe MJ, et al. (2005) American College of Radiology Imaging Network digital mammographic imaging screening trial: objectives and methodology. Radiology 236(2): 404–412PubMedCrossRefGoogle Scholar
  138. 138.
    Pisano ED, Hendrick RE, Yaffe MJ, et al. (2008) Diagnostic accuracy of digital versus film mammography: exploratory analysis of selected population subgroups in DMIST. Radiology 246(2): 376–383PubMedCrossRefGoogle Scholar
  139. 139.
    Pittinger TP, Maronian NC, Poulter CA, Peacock JL (1994) Importance of margin status in outcome of breast-conserving surgery for carcinoma. Surgery 116: 605–608; discussion 608–9PubMedGoogle Scholar
  140. 140.
    Polyak K (2006) Pregnancy and breast cancer: the other side of the coin. Cancer Cell 9: 151–153PubMedCrossRefGoogle Scholar
  141. 141.
    Pritchard KI (2007) Adjuvant therapy of the very young woman. Breast 16(Suppl 2): S136–S146PubMedCrossRefGoogle Scholar
  142. 142.
    Rebbeck TR, Friebel T, Lynch HT, et al. (2004) Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol 22(6): 1055–1062PubMedCrossRefGoogle Scholar
  143. 143.
    Recchia F, Saggio G, Amiconi G, et al. (2006) Gonadotropin-releasing hormone analogues added to adjuvant chemotherapy protect ovarian function and improve clinical outcomes in young women with early breast carcinoma. Cancer 106(3): 514–523PubMedCrossRefGoogle Scholar
  144. 144.
    Recommandations pour la pratique clinique de Saint-Paul-de-Vence (2007) Oncologie 9: 593–644CrossRefGoogle Scholar
  145. 145.
    Regan MM, Pagani O, Walley B, et al. (2008) Premenopausal endocrine-responsive early breast cancer: who receives chemotherapy? Ann Oncol 19(7): 1231–1241PubMedCrossRefGoogle Scholar
  146. 146.
    Ring AE, Smith IE, Ellis PA (2005) Breast cancer and pregnancy. Ann Oncol 16: 1855–1860PubMedCrossRefGoogle Scholar
  147. 147.
    Robson M, Offit K (2007) Clinical practice. Management of an inherited predisposition to breast cancer. N Engl J Med 357(2): 154–162PubMedCrossRefGoogle Scholar
  148. 148.
    Robson M, Svahn T, McCormick B, et al. (2005) Appropriateness of breast-conserving treatment of breast carcinoma in women with germline mutations in BRCA1 or BRCA2: a clinic-based series. Cancer 103(1): 44–51PubMedCrossRefGoogle Scholar
  149. 149.
    Rosato RM, Dowden RV (1994) Radiation therapy as a cause of capsular contracture. Ann Plast Surg 32: 342–345PubMedCrossRefGoogle Scholar
  150. 150.
    Rose MA, Henderson, IC, Gelman, R, et al. (1989) Premenopausal breast cancer patients treated with conservative surgery, radiotherapy and adjuvant chemotherapy have a low-risk of local failure. Int J Radiat Oncol Biol Phys 17: 711–717PubMedGoogle Scholar
  151. 151.
    Rouzier R, Extra JM, Carton M, et al. (2001) Primary chemotherapy for operable breast cancer: incidence and prognostic significance of ipsilateral breast tumor recurrence after breast-conserving surgery. J Clin Oncol 19: 3828–3835PubMedGoogle Scholar
  152. 152.
    Rubin P, O’Hanlon D, Browell D, et al. (1996) Tumor bed biopsy detects the presence of multifocal disease in patients undergoing breast conservation therapy for primary breast carcinoma. Eur J Surg Oncol 22: 23–26PubMedCrossRefGoogle Scholar
  153. 153.
    Sanghani M, Balk E, Cady B, Wazer D (2007) Predicting the risk of local recurrence in patients with breast cancer: an approach to a new computer-based predictive tool. Am J Clin Oncol 30: 473–480PubMedCrossRefGoogle Scholar
  154. 154.
    Sardanelli F, Giuseppetti GM, Panizza P, et al. (2004) Sensitivity of MRI versus mammography for detecting foci of multifocal, multicentric breast cancer infatty and dense breasts using the whole-breast pathologic examination as a gold standard. AJR 183: 1149–1157PubMedGoogle Scholar
  155. 155.
    Saslow D, Boetes C, Burke W, et al. (2007) American Cancer Society Breast Cancer Advisory Group. CA Cancer J Clin 57(2): 75–89PubMedCrossRefGoogle Scholar
  156. 156.
    Schedin P (2006) Pregnancy-associated breast cancer and metastasis. Nat Rev Cancer 6: 281–291PubMedCrossRefGoogle Scholar
  157. 157.
    Schnall MD, Blume J, Bluemke DA, et al. (2005) MRI detection of distinct incidental cancer in women with primary breast cancer studied in IBMC 6883. J Surg Oncol 92: 32–38PubMedCrossRefGoogle Scholar
  158. 158.
    Shahedi K, Emanuelsson M, Wiklund F, Gronberg H (2006) Highrisk of contralateral breast carcinoma in women with hereditary/familial non-BRCA1/BRCA2 breast carcinoma. Cancer 106(6): 1237–1242PubMedCrossRefGoogle Scholar
  159. 159.
    Sharma R, Hamilton A, Beith J (2008) LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women. Cochrane Database Syst Rev (4): CD004562PubMedGoogle Scholar
  160. 160.
    Smith TE, Lee D, Turner BC, et al. (2000) True recurrence vs new primary ipsilateral breast tumor relapse: an analysis of clinical and pathologic differences and their implications in natural history, prognoses, and therapeutic management. Int J Radiat Oncol Biol Phys 48: 1281–1289PubMedGoogle Scholar
  161. 161.
    Solin LJ, Orel SG, Hwang WT, et al. (2008) Relationship of breast magnetic resonance imaging to outcome after breastconservation treatment with radiation for women with earlystage invasive breast carcinoma or ductal carcinoma in situ. J Clin Oncol 26: 386–391PubMedCrossRefGoogle Scholar
  162. 162.
    Son EJ, Oh KK, Kim EK (2006) Pregnancy-associated breast disease: radiologic features and diagnostic dilemmas. Yonsei Med J 47: 34–42PubMedCrossRefGoogle Scholar
  163. 163.
    Sunyoung LEE (2009) Chemotherapy-related amenorrhea in premenopausal women with breast cancer. Menopause 16(1): 98–103CrossRefGoogle Scholar
  164. 164.
    Tahir M, Osman KA, Shabbir J, et al. (2008) Preoperative axillary staging in breast cancer-saving time and resources. Breast J 14: 369–371PubMedCrossRefGoogle Scholar
  165. 165.
    Tai P, et al. (2005) modeling the effectof age in T1–2-breast cancer using the SEER database. BMC Cancer 5: 130–138PubMedCrossRefGoogle Scholar
  166. 166.
    Thewes B, Meiser B, Duric VM, et al. (2005) What survival benefits do premenopausal patients with early breast cancer need to make endocrine therapy worthwhile? Lancet Oncol 6(8): 581–588PubMedCrossRefGoogle Scholar
  167. 167.
    Tilanus-Linthorst MM, Alves C, Seynaeve C, et al. (2006) Contralateral recurrence and prognostic factors in familial non-BRCA1/2-associated breast cancer. Br J Surg 93(8): 961–968PubMedCrossRefGoogle Scholar
  168. 168.
    Tinger A, Wasserman TH, Klein EE, et al. (1997) The incidence of breast cancer following mantle field radiation therapy as a function of dose and technique. Int J Radiat Oncol Biol Phys 37: 865–870PubMedGoogle Scholar
  169. 169.
    Tuttle TM, Habermann EB, Grund EH, et al. (2007) Increasing use of contralateral prophylactic mastectomy for breast cancer patients: a trend toward more aggressive surgical treatment. J Clin Oncol 25(33): 5203–5209PubMedCrossRefGoogle Scholar
  170. 170.
    Tuttle TM (2009) Magnetic resonance imaging and contralateral prophylactic mastectomy: the “no más” effect? Ann Surg Oncol 16(6): 1461–1462PubMedCrossRefGoogle Scholar
  171. 171.
    van der Leest M, Evers L, van der Sangen MJ, et al. (2007) The safety of breast-conserving therapy in patients with breast cancer aged of more or less 40 years. Cancer 109: 1957–1964PubMedCrossRefGoogle Scholar
  172. 172.
    van Dongen JA, Voogd AC, Fentiman IS, et al. (2000) Long-term results of a randomized trial comparing breast-conserving therapy with mastectomy: European Organization for Research and Treatment of Cancer 10801 trial. J Natl Cancer Inst 92: 1143–1150PubMedCrossRefGoogle Scholar
  173. 173.
    van Sprundel TC, Schmidt MK, Rookus MA, et al. (2005) Risk reduction of contralateral breast cancer and survival after contralateral prophylactic mastectomy in BRCA1 or BRCA2 mutation carriers. Br J Cancer 93(3): 287–292PubMedCrossRefGoogle Scholar
  174. 174.
    Verhoog LC, Brekelmans CT, Seynaeve C, et al. (2000) Contralateral breast cancer risk is influenced by the age at onset in BRCA1-associated breast cancer. Br J Cancer 83(3): 384–386PubMedCrossRefGoogle Scholar
  175. 175.
    Veronesi U, Cascinelli N, Mariani L, et al. (2002) Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med 347: 1227–1232PubMedCrossRefGoogle Scholar
  176. 176.
    Veronesi U, Marubini E, Del Vecchio M, et al. (1995) Local recurrences and distant metastases after conservative breast cancer treatments: partly independent events. J Natl Cancer Inst 87: 19–27PubMedCrossRefGoogle Scholar
  177. 177.
    Veronesi U, Marubini E, Mariani L, et al. (2001) Radiotherapy after breast-conserving surgery in small breast carcinoma: long-term results of a randomized trial. Ann Oncol 12: 997–1003PubMedCrossRefGoogle Scholar
  178. 178.
    Vicini FA, Recht A, Abner A, et al. (1992) Recurrence in the breast following conservative surgery and radiation therapy for early-stage breast cancer. J Natl Cancer Inst Monogr: 33–39Google Scholar
  179. 179.
    Vrieling C, Collette L, Fourquet A, et al. (2003) Can patient-, treatment- and pathology-related characteristics explain the high local recurrence rate following breast-conserving therapy in young patients? Eur J Cancer 39: 932–944PubMedCrossRefGoogle Scholar
  180. 180.
    Vu-Nishino H, Tavassoli FA, Ahrens WA, Haffty BG (2005) Clinicopathologic features and long-term outcome of patients with medullary breast carcinoma managed with breast-conserving therapy (BCT). Int J Radiat Oncol Biol Phys 62: 1040–1047PubMedGoogle Scholar
  181. 181.
    Walsche JM (2006) Amenorrhea in premenopausal women after adjuvant chemotherapy for breast cancer. J Clin Oncol 24(36): 5769–5779CrossRefGoogle Scholar
  182. 182.
    Warner E, Messersmith H, Causer P, et al. (2008) Systematic review: using magnetic resonance imaging to screen women at high-risk for breast cancer. Ann Intern Med 148(9): 671–679PubMedGoogle Scholar
  183. 183.
    Warner E, (2004) Surveillance of BRCA1 and BRCA2 Mutation carriers with magnetic resonnance imaging, ultrasound, mammographie and clinical examination. JAMA 292(11): 1317–1325PubMedCrossRefGoogle Scholar
  184. 184.
    Wazer DE, Gage I, Homer MJ, et al. (1996) Age-related differences in patients with non-palpable breast carcinomas. Cancer 78: 1432–437PubMedCrossRefGoogle Scholar
  185. 185.
    Wazer DE, Schmidt-Ullrich RK, Schmid CH, et al. (1997) The value of breast lumpectomy margin assessment as a predictor of residual tumor burden. Int J Radiat Oncol Biol Phys 38: 291–299PubMedGoogle Scholar
  186. 186.
    Whelan TJ, Loprinzi C (2005) Physician-patient decision AIDS for adjuvant therapy. J Clin Oncol 23(8): 1627–1630PubMedCrossRefGoogle Scholar
  187. 187.
    Witzel ID, Muller V, Harps E, et al. (2008) Trastuzumab in pregnancy associated with poor fetal outcome. Ann Oncol 19: 191–192PubMedCrossRefGoogle Scholar
  188. 188.
    Wong EK, Truong PT, Kader HA, et al. (2006) Consistency in seroma contouring for partial breast radiotherapy: impact of guidelines. Int J Radiat Oncol Biol Phys 66: 372–376PubMedGoogle Scholar
  189. 189.
    Wood WC (2008) Increasing use of contralateral prophylactic mastectomy: a counter-intuitive trend. Oncology (Williston Park) 22(5): 548–551Google Scholar
  190. 190.
    Xiong Q, Valero V, Kau V, et al. (2001) Female patients with breast carcinoma age 30 years and younger have a poor prognosis: the MD Anderson Cancer Center experience. Cancer 92: 2523–2528PubMedCrossRefGoogle Scholar
  191. 191.
    Zabicki K, Colbert JA, Dominguez FJ, et al. (2006) Breast cancer diagnosis in women more or less 40 versus 50 to 60 years: increasing size and stage disparity compared with older women over time. Ann Surg Oncol 13: 1072–1077PubMedCrossRefGoogle Scholar

Copyright information

© Springer Verlag France 2009

Personalised recommendations